Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
- Keywords
- Chronic myeloid leukemia, chronic phase, daily clinical practice, dasatinib, imatinib, second line,
- MeSH
- Leukemia, Myeloid, Chronic-Phase * drug therapy genetics MeSH
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive * drug therapy genetics MeSH
- Dasatinib adverse effects MeSH
- Imatinib Mesylate adverse effects MeSH
- Protein Kinase Inhibitors adverse effects MeSH
- Humans MeSH
- Retrospective Studies MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Dasatinib MeSH
- Imatinib Mesylate MeSH
- Protein Kinase Inhibitors MeSH
To evaluate long-term real-life results of dasatinib therapy among chronic phase chronic myeloid leukemia patients resistant or intolerant to imatinib, we retrospectively analyzed data of 118 patients treated in centers participating in the database INFINITY. With median follow-up of 37 months, estimated 5-year cumulative incidences of complete cytogenetic and major molecular responses were 78% and 68%, respectively. The estimated 5-year probability of overall survival (OS) and event-free survival (EFS) were 86% and 83%, respectively. Both OS and EFS were significantly improved among patients with BCR-ABL1 transcript level ≤10% at 3 months. Dasatinib toxicity was tolerable however persistent in almost half our patients, even after years of therapy. Pleural effusion occurred in 29% of patients and was responsible for 30% of dasatinib discontinuations. Our results confirmed very good efficacy and acceptable toxicity of dasatinib in second line setting and support the evidence and importance of high-quality real-life CML patient management.
Central European Institute of Technology Brno Czech Republic
Department of Hematooncology University Hospital Ostrava Ostrava Czech Republic
Institute of Biostatistics and Analyses Ltd Brno Czech Republic
Institute of Hematology and Blood Transfusion Praha Czech Republic
References provided by Crossref.org
